301 related articles for article (PubMed ID: 35545792)
1. Diagnostic value of serum versus plasma phospho-tau for Alzheimer's disease.
Kac PR; Gonzalez-Ortiz F; Simrén J; Dewit N; Vanmechelen E; Zetterberg H; Blennow K; Ashton NJ; Karikari TK
Alzheimers Res Ther; 2022 May; 14(1):65. PubMed ID: 35545792
[TBL] [Abstract][Full Text] [Related]
2. Clinical performance and head-to-head comparison of CSF p-tau235 with p-tau181, p-tau217 and p-tau231 in two memory clinic cohorts.
Lantero-Rodriguez J; Vrillon A; Fernández-Lebrero A; Ortiz-Romero P; Snellman A; Montoliu-Gaya L; Brum WS; Cognat E; Dumurgier J; Puig-Pijoan A; Navalpotro-Gómez I; García-Escobar G; Karikari TK; Vanmechelen E; Ashton NJ; Zetterberg H; Suárez-Calvet M; Paquet C; Blennow K
Alzheimers Res Ther; 2023 Mar; 15(1):48. PubMed ID: 36899441
[TBL] [Abstract][Full Text] [Related]
3. Plasma p-tau231: a new biomarker for incipient Alzheimer's disease pathology.
Ashton NJ; Pascoal TA; Karikari TK; Benedet AL; Lantero-Rodriguez J; Brinkmalm G; Snellman A; Schöll M; Troakes C; Hye A; Gauthier S; Vanmechelen E; Zetterberg H; Rosa-Neto P; Blennow K
Acta Neuropathol; 2021 May; 141(5):709-724. PubMed ID: 33585983
[TBL] [Abstract][Full Text] [Related]
4. Greater specificity for cerebrospinal fluid P-tau231 over P-tau181 in the differentiation of healthy controls from Alzheimer's disease.
Spiegel J; Pirraglia E; Osorio RS; Glodzik L; Li Y; Tsui W; Saint Louis LA; Randall C; Butler T; Xu J; Zinkowski RP; Zetterberg H; Fortea J; Fossati S; Wisniewski T; Davies P; Blennow K; de Leon MJ
J Alzheimers Dis; 2016; 49(1):93-100. PubMed ID: 26444757
[TBL] [Abstract][Full Text] [Related]
5. Trajectories of CSF and plasma biomarkers across Alzheimer's disease continuum: disease staging by NF-L, p-tau181, and GFAP.
Wojdała AL; Bellomo G; Gaetani L; Toja A; Chipi E; Shan D; Chiasserini D; Parnetti L
Neurobiol Dis; 2023 Dec; 189():106356. PubMed ID: 37977432
[TBL] [Abstract][Full Text] [Related]
6. Association of Phosphorylated Tau Biomarkers With Amyloid Positron Emission Tomography vs Tau Positron Emission Tomography.
Therriault J; Vermeiren M; Servaes S; Tissot C; Ashton NJ; Benedet AL; Karikari TK; Lantero-Rodriguez J; Brum WS; Lussier FZ; Bezgin G; Stevenson J; Rahmouni N; Kunach P; Wang YT; Fernandez-Arias J; Socualaya KQ; Macedo AC; Ferrari-Souza JP; Ferreira PCL; Bellaver B; Leffa DT; Zimmer ER; Vitali P; Soucy JP; Triana-Baltzer G; Kolb HC; Pascoal TA; Saha-Chaudhuri P; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
JAMA Neurol; 2023 Feb; 80(2):188-199. PubMed ID: 36508198
[TBL] [Abstract][Full Text] [Related]
7. Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies.
Gonzalez MC; Ashton NJ; Gomes BF; Tovar-Rios DA; Blanc F; Karikari TK; Mollenhauer B; Pilotto A; Lemstra A; Paquet C; Abdelnour C; Kramberger MG; Bonanni L; Vandenberghe R; Hye A; Blennow K; Zetterberg H; Aarsland D;
JAMA Neurol; 2022 Jan; 79(1):32-37. PubMed ID: 34807233
[TBL] [Abstract][Full Text] [Related]
8. Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231.
Bayoumy S; Verberk IMW; den Dulk B; Hussainali Z; Zwan M; van der Flier WM; Ashton NJ; Zetterberg H; Blennow K; Vanbrabant J; Stoops E; Vanmechelen E; Dage JL; Teunissen CE
Alzheimers Res Ther; 2021 Dec; 13(1):198. PubMed ID: 34863295
[TBL] [Abstract][Full Text] [Related]
9. Differences Between Plasma and Cerebrospinal Fluid p-tau181 and p-tau231 in Early Alzheimer's Disease.
Pilotto A; Parigi M; Bonzi G; Battaglio B; Ferrari E; Mensi L; Benussi A; Caratozzolo S; Cosseddu M; Turrone R; Archetti S; Ashton NJ; Zetterberg H; Giliani S; Padovani A
J Alzheimers Dis; 2022; 87(3):991-997. PubMed ID: 35404280
[TBL] [Abstract][Full Text] [Related]
10. Comparing the Clinical Utility and Diagnostic Performance of CSF P-Tau181, P-Tau217, and P-Tau231 Assays.
Leuzy A; Janelidze S; Mattsson-Carlgren N; Palmqvist S; Jacobs D; Cicognola C; Stomrud E; Vanmechelen E; Dage JL; Hansson O
Neurology; 2021 Oct; 97(17):e1681-e1694. PubMed ID: 34493616
[TBL] [Abstract][Full Text] [Related]
11. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts.
Karikari TK; Pascoal TA; Ashton NJ; Janelidze S; Benedet AL; Rodriguez JL; Chamoun M; Savard M; Kang MS; Therriault J; Schöll M; Massarweh G; Soucy JP; Höglund K; Brinkmalm G; Mattsson N; Palmqvist S; Gauthier S; Stomrud E; Zetterberg H; Hansson O; Rosa-Neto P; Blennow K
Lancet Neurol; 2020 May; 19(5):422-433. PubMed ID: 32333900
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head study of diagnostic accuracy of plasma and cerebrospinal fluid p-tau217 versus p-tau181 and p-tau231 in a memory clinic cohort.
Mendes AJ; Ribaldi F; Lathuiliere A; Ashton NJ; Janelidze S; Zetterberg H; Scheffler M; Assal F; Garibotto V; Blennow K; Hansson O; Frisoni GB
J Neurol; 2024 Apr; 271(4):2053-2066. PubMed ID: 38195896
[TBL] [Abstract][Full Text] [Related]
13. Plasma p-tau231, p-tau181, PET Biomarkers, and Cognitive Change in Older Adults.
Meyer PF; Ashton NJ; Karikari TK; Strikwerda-Brown C; Köbe T; Gonneaud J; Pichet Binette A; Ozlen H; Yakoub Y; Simrén J; Pannee J; Lantero-Rodriguez J; Labonté A; Baker SL; Schöll M; Vanmechelen E; Breitner JCS; Zetterberg H; Blennow K; Poirier J; Villeneuve S;
Ann Neurol; 2022 Apr; 91(4):548-560. PubMed ID: 35084051
[TBL] [Abstract][Full Text] [Related]
14. Equivalence of plasma p-tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease.
Therriault J; Servaes S; Tissot C; Rahmouni N; Ashton NJ; Benedet AL; Karikari TK; Macedo AC; Lussier FZ; Stevenson J; Wang YT; Fernandez-Arias J; Stevenson A; Socualaya KQ; Haeger A; Nazneen T; Aumont É; Hosseini A; Rej S; Vitali P; Triana-Baltzer G; Kolb HC; Soucy JP; Pascoal TA; Gauthier S; Zetterberg H; Blennow K; Rosa-Neto P
Alzheimers Dement; 2023 Nov; 19(11):4967-4977. PubMed ID: 37078495
[TBL] [Abstract][Full Text] [Related]
15. Plasma and CSF biomarkers in a memory clinic: Head-to-head comparison of phosphorylated tau immunoassays.
Ashton NJ; Puig-Pijoan A; Milà-Alomà M; Fernández-Lebrero A; García-Escobar G; González-Ortiz F; Kac PR; Brum WS; Benedet AL; Lantero-Rodriguez J; Day TA; Vanbrabant J; Stoops E; Vanmechelen E; Triana-Baltzer G; Moughadam S; Kolb H; Ortiz-Romero P; Karikari TK; Minguillon C; Hernández Sánchez JJ; Navalpotro-Gómez I; Grau-Rivera O; María Manero R; Puente-Periz V; de la Torre R; Roquer J; Dage JL; Zetterberg H; Blennow K; Suárez-Calvet M
Alzheimers Dement; 2023 May; 19(5):1913-1924. PubMed ID: 36370462
[TBL] [Abstract][Full Text] [Related]
16. Head-to-head comparison of 10 plasma phospho-tau assays in prodromal Alzheimer's disease.
Janelidze S; Bali D; Ashton NJ; Barthélemy NR; Vanbrabant J; Stoops E; Vanmechelen E; He Y; Dolado AO; Triana-Baltzer G; Pontecorvo MJ; Zetterberg H; Kolb H; Vandijck M; Blennow K; Bateman RJ; Hansson O
Brain; 2023 Apr; 146(4):1592-1601. PubMed ID: 36087307
[TBL] [Abstract][Full Text] [Related]
17. Phospho-specific plasma p-tau181 assay detects clinical as well as asymptomatic Alzheimer's disease.
De Meyer S; Vanbrabant J; Schaeverbeke JM; Reinartz M; Luckett ES; Dupont P; Van Laere K; Stoops E; Vanmechelen E; Poesen K; Vandenberghe R
Ann Clin Transl Neurol; 2022 May; 9(5):734-746. PubMed ID: 35502634
[TBL] [Abstract][Full Text] [Related]
18. Diagnostic and prognostic plasma biomarkers for preclinical Alzheimer's disease.
Chatterjee P; Pedrini S; Ashton NJ; Tegg M; Goozee K; Singh AK; Karikari TK; Simrén J; Vanmechelen E; Armstrong NJ; Hone E; Asih PR; Taddei K; Doré V; Villemagne VL; Sohrabi HR; Zetterberg H; Masters CL; Blennow K; Martins RN
Alzheimers Dement; 2022 Jun; 18(6):1141-1154. PubMed ID: 34494715
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Plasma Phosphorylated Tau Species With Amyloid and Tau Positron Emission Tomography, Neurodegeneration, Vascular Pathology, and Cognitive Outcomes.
Mielke MM; Frank RD; Dage JL; Jeromin A; Ashton NJ; Blennow K; Karikari TK; Vanmechelen E; Zetterberg H; Algeciras-Schimnich A; Knopman DS; Lowe V; Bu G; Vemuri P; Graff-Radford J; Jack CR; Petersen RC
JAMA Neurol; 2021 Sep; 78(9):1108-1117. PubMed ID: 34309632
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic value of plasma p-tau181, NfL, and GFAP in a clinical setting cohort of prevalent neurodegenerative dementias.
Baiardi S; Quadalti C; Mammana A; Dellavalle S; Zenesini C; Sambati L; Pantieri R; Polischi B; Romano L; Suffritti M; Bentivenga GM; Randi V; Stanzani-Maserati M; Capellari S; Parchi P
Alzheimers Res Ther; 2022 Oct; 14(1):153. PubMed ID: 36221099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
